Dr. Pulsipher is the Division Chief of Pediatric Hematology and Oncology at Intermountain Primary Children’s Hospital, Director of the Children’s and Adolescent Cancer Initiative at the Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah. He is a past Group Chair of the Pediatric Transplantation and Cellular Therapy Consortium, an 86-member international clinical trials
group, and is recognized as a leading influence in his field, receiving the PTCTC Lifetime Achievement Award in 2020 and the George R. Buchanan Award for teaching and mentorship in 2023 by The American Society of Pediatric Hematology/Oncology. He is currently principal or coprincipal investigator of four NIH-funded national, multicenter studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 320 articles in peer-reviewed journals and written 20 book chapters. His research interests include allogeneic transplantation and cell therapy for acute leukemias, especially ALL, where he is running innovative trials aimed at identifying patients able to undergo less intensive BMT approaches. Dr. Pulsipher’s work in cell therapy helped lead to the FDA approval of the first CAR T cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. Dr. Pulsipher is passionate about minimizing harms associated with transplant has done extensive work in reduced toxicity approaches to transplantation of both malignant and nonmalignant disorders, running national protocols for patients with immunodeficiencies, HLH, and bone marrow failure. Finally, he has performed several large trials assessing the safety and Quality of Life of pediatric hematopoietic stem
cell donors and is currently running a large trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.